home / stock / sabsw / sabsw quote
Last: | $0.0304 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.0304 |
High: | $0 |
Low: | $0 |
Volume: | 14 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.0304 | $0 | $0.0304 | $0 | $0 | 14 | 04-25-2024 |
$0.0304 | $0.03 | $0.0304 | $0.0304 | $0.03 | 3,200 | 04-10-2024 |
$0.030101 | $0 | $0.030101 | $0 | $0 | 26 | 04-09-2024 |
$0.030101 | $0.030101 | $0.030101 | $0.030101 | $0.030101 | 101 | 04-03-2024 |
$0.0316 | $0.04294 | $0.0316 | $0.04294 | $0.0304 | 7,150 | 04-01-2024 |
$0.039 | $0.039 | $0.039 | $0.039 | $0.039 | 1,040 | 03-26-2024 |
$0.0365 | $0.0376 | $0.0365 | $0.0425 | $0.03 | 15,300 | 03-25-2024 |
$0.037001 | $0.0366 | $0.037001 | $0.037401 | $0.0366 | 2,278 | 03-22-2024 |
$0.0366 | $0.036799 | $0.0366 | $0.036799 | $0.0366 | 2,056 | 03-20-2024 |
$0.0355 | $0.0355 | $0.0355 | $0.0369 | $0.0355 | 2,787 | 03-19-2024 |
$0.0301 | $0.0304 | $0.0301 | $0.0304 | $0.03 | 1,355 | 03-18-2024 |
$0.0303 | $0.03 | $0.0303 | $0.0489 | $0.03 | 7,542 | 03-15-2024 |
$0.03 | $0.03 | $0.03 | $0.0303 | $0.03 | 23,200 | 03-14-2024 |
$0.034999 | $0.03 | $0.034999 | $0.034999 | $0.03 | 405 | 03-07-2024 |
$0.03 | $0.0303 | $0.03 | $0.0303 | $0.03 | 800 | 03-06-2024 |
$0.035 | $0.0329 | $0.035 | $0.035 | $0.03 | 4,013 | 03-04-2024 |
$0.03 | $0.03 | $0.03 | $0.03 | $0.03 | 546 | 03-01-2024 |
$0.032 | $0.0323 | $0.032 | $0.0379 | $0.032 | 8,882 | 02-29-2024 |
$0.03 | $0.03 | $0.03 | $0.0338 | $0.03 | 668 | 02-28-2024 |
$0.0339 | $0.033949 | $0.0339 | $0.0379 | $0.0339 | 3,185 | 02-27-2024 |
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc. Warrant Company Name:
SABSW Stock Symbol:
NASDAQ Market:
MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIg...
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biop...
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIg...